Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina. Show more

4020 Stirrup Creek Drive, Durham, NC, 27703, United States

Biotechnology

Healthcare

Market Cap

68.45M

52 Wk Range

$9.00 - $54.29

Previous Close

$21.30

Open

$20.40

Volume

10,038

Day Range

$20.40 - $21.35

Enterprise Value

88.33M

Cash

17.97M

Avg Qtr Burn

-6.252M

Insider Ownership

49.99%

Institutional Own.

33.17%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Xepi/Ozenoxacin (Quinolone Antibiotic) Details Impetigo	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Xeglyze/Abametapir (Metalloproteinase Inhibitor) Details Head Lice Infestation	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zelsuvmi/Berdazimer (Nitric Oxide Donor) Details Molluscum Contagiosum	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CT2000 (NaV1.7 Inhibitor) Details Dry Eye Disease With Chronic Eye Pain	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.